Nuvectis Pharma Inc reports results for the quarter ended in March - Earnings Summary

Nuvectis Pharma

07/05/2024 14:46

* Nuvectis Pharma Inc  NVCT.OQ  reported a quarterly
adjusted loss
of 25 cents​​ per share for the quarter ended in March, higher
than the same quarter last year, when the company reported EPS
of -27 cents.  The mean expectation of three analysts for the
quarter was for a loss of 40 cents per share. Wall Street
expected results to range from -40 cents to -39 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Nuvectis Pharma Inc's reported EPS for the quarter was a
loss
of 25 cents​.
    * The company reported a quarterly loss of $4.17 million.
    * Nuvectis Pharma Inc shares had fallen by 7.8% this
quarter and
lost 9.4% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 7.6%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Nuvectis Pharma
Inc is $21.00 
This summary was machine generated from LSEG data May 7 at 01:46
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.40          -0.25          Beat
 Dec. 31 2023      -0.36          -0.41          Missed
 Sep. 30 2023      -0.34          -0.37          Missed
 Jun. 30 2023      -0.29          -0.38          Missed